Overview

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix's lead product candidate, Tonmya, or TNX-102 SL, is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer's disease. A Phase 2 IND (Investigational New Drug) application was submitted in March 2018 after completion of a successful pre-IND meeting with the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but designed for daytime dosing. Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.

Seth Lederman, MD

Co-Founder, CEO & Chairman

Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage…

View Full Bio

Gregory Sullivan, MD

Chief Medical Officer

Dr. Sullivan is a physician and scientist. Dr. Sullivan joined Tonix Pharmaceuticals from Columbia University (CU), where he was most recently an Assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University…

View Full Bio

Bradley Saenger, CPA

Chief Financial Officer

Bradley Saenger joined Tonix in May 2014, as Director of Accounting (May 2014 – December 2015) and was promoted to VP of Accounting (January 2016 – February 2016) and to Chief Financial Officer (February 2016). Mr. Saenger has…

View Full Bio

Jessica Edgar Morris

Chief Operating Officer

Jessica Edgar Morris joined Tonix Pharmaceuticals as Senior Vice President of Finance in September 2013. Ms. Morris served as Acting Chief Financial Officer from January 2016 to February 2016 and was subsequently appointed Executive Vice…

View Full Bio

Mark T. Edgar, PhD

Senior Vice President of Product Development

Dr. Edgar brings to Tonix over 25 years of experience in pharmaceutical development and commercialization. He has extensive expertise in advancing research-stage pharmaceutical candidates to commercialization, and has authored chemistry,…

View Full Bio

Seth Lederman, MD

Co-Founder, CEO & Chairman

View Full Bio

Margaret Smith Bell

Director

Margaret Smith Bell was a Vice President at Standard Life Investments where she was a portfolio manager and health care equity analyst. Previously, Ms. Bell was a Managing Director at Putnam Investments, and served as a senior health care…

View Full Bio

Patrick P. Grace

Director

Mr. Grace is Managing Partner of Apollo Philanthropy Partners, LLC, a New York-based strategic consulting firm serving private philanthropists and the nonprofit sector. Mr. Grace is an experienced senior executive with expertise in…

View Full Bio

General David Grange (ret)

Director

General Grange is currently Chief Executive Officer of Pharm-Olam International, Ltd. Prior to joining Pharm-Olam, he was President of Osprey Global Solutions, LLC “OGS”, a Service Disabled Veterans Organization. Gen. Grange…

View Full Bio

Donald W. Landry, MD, PhD

Director, Co-Founder

Dr. Landry is the Samuel Bard Professor and Chair of the Department of Medicine (tenured) at Columbia University's College of Physicians and Surgeons. Dr. Landry also serves as Director of the Division of Experimental Therapeutics. Dr.…

View Full Bio

Ernest Mario, PhD

Director

Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario served in management at a number of drug companies before being named in 1989…

View Full Bio

Charles E. Mather

Director

Mr. Mather served as a Managing Director at Janney Capital Markets from 2009 to 2015. He was most recently Co-Head of the Equity Capital Markets Group where he was responsible for public offerings, private placements, PIPES, registered…

View Full Bio

John Rhodes

Director

Mr. Rhodes is the President and CEO of the New York State Energy Research and Development Authority (NYSERDA), a public benefit corporation which offers information and analysis, technical expertise and funding to help New Yorkers increase…

View Full Bio

Samuel Saks, MD

Director

Dr. Saks is former CEO of Jazz Pharmaceuticals (Nasdaq: JAZZ), which he co-founded in 2003. At Jazz, Dr. Saks was responsible for the commercialization of Xyrem® (sodium oxybate) for cataplexy and excessive daytime sleepiness…

View Full Bio

Investor Relations
TONIX Pharmaceuticals
investor.relations@tonixpharma.com

Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com

Investors

Latest News

Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium

Upcoming Event

2018 Military Health System Research Symposium (MHSRS)

Latest Financial Results

Latest Annual Report

10-K

Stock Information

Symbol

Price

Change

MKT Cap

Volume

52 week Low/High

Day Low/High

Company Overview

Officers & Directors

Seth Lederman, MD

Gregory Sullivan, MD

Bradley Saenger, CPA

Jessica Edgar Morris

Mark T. Edgar, PhD

Seth Lederman, MD

Margaret Smith Bell

Patrick P. Grace

General David Grange (ret)

Donald W. Landry, MD, PhD

Ernest Mario, PhD

Charles E. Mather

John Rhodes

Samuel Saks, MD

IR Contact Information

Investor Relations

Investors

Latest News

Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium

Upcoming Event

2018 Military Health System Research Symposium (MHSRS)

Sign up for email alerts

Latest Financial Results

Latest Annual Report

10-K

Stock Information

Symbol

Price

Change

MKT Cap

Volume

52 week Low/High

Day Low/High

Company Overview

Officers & Directors

Seth Lederman, MD

Gregory Sullivan, MD

Bradley Saenger, CPA

Jessica Edgar Morris

Mark T. Edgar, PhD

Seth Lederman, MD

Margaret Smith Bell

Patrick P. Grace

General David Grange (ret)

Donald W. Landry, MD, PhD

Ernest Mario, PhD

Charles E. Mather

John Rhodes

Samuel Saks, MD

IR Contact Information